Heska Competitors

Heska (NASDAQ:HSKA) and Quidel (NASDAQ:QDEL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Earnings and Valuation

This table compares Heska and Quidel's revenue, earnings per share and valuation.

Quidel has higher revenue and earnings than Heska. Quidel is trading at a lower price-to-earnings ratio than Heska, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Heska and Quidel, as reported by MarketBeat.com.

Heska currently has a consensus price target of $185.80, indicating a potential upside of 8.22%. Quidel has a consensus price target of $245.60, indicating a potential upside of 62.33%. Given Quidel's higher possible upside, analysts clearly believe Quidel is more favorable than Heska.

Profitability

This table compares Heska and Quidel's net margins, return on equity and return on assets.

Institutional & Insider Ownership

96.1% of Heska shares are held by institutional investors. Comparatively, 84.0% of Quidel shares are held by institutional investors. 11.7% of Heska shares are held by insiders. Comparatively, 14.1% of Quidel shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Heska has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Quidel has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500.

Summary

Quidel beats Heska on 9 of the 14 factors compared between the two stocks.

Neogen (NASDAQ:NEOG) and Heska (NASDAQ:HSKA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.

Risk & Volatility

Neogen has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Heska has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500.

Earnings & Valuation

This table compares Neogen and Heska's revenue, earnings per share and valuation.

Neogen has higher revenue and earnings than Heska. Neogen is trading at a lower price-to-earnings ratio than Heska, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Neogen and Heska's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Neogen and Heska, as provided by MarketBeat.

Neogen currently has a consensus target price of $81.50, indicating a potential upside of 2.19%. Heska has a consensus target price of $185.80, indicating a potential upside of 8.22%. Given Heska's stronger consensus rating and higher probable upside, analysts clearly believe Heska is more favorable than Neogen.

Insider & Institutional Ownership

92.8% of Neogen shares are owned by institutional investors. Comparatively, 96.1% of Heska shares are owned by institutional investors. 0.9% of Neogen shares are owned by insiders. Comparatively, 11.7% of Heska shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Heska (NASDAQ:HSKA) and Intellia Therapeutics (NASDAQ:NTLA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Profitability

This table compares Heska and Intellia Therapeutics' net margins, return on equity and return on assets.

Volatility and Risk

Heska has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500.

Earnings & Valuation

This table compares Heska and Intellia Therapeutics' top-line revenue, earnings per share and valuation.

Heska has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Heska, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Heska and Intellia Therapeutics, as reported by MarketBeat.com.

Heska currently has a consensus price target of $185.80, suggesting a potential upside of 8.22%. Intellia Therapeutics has a consensus price target of $56.6154, suggesting a potential upside of 9.28%. Given Intellia Therapeutics' higher possible upside, analysts plainly believe Intellia Therapeutics is more favorable than Heska.

Institutional & Insider Ownership

96.1% of Heska shares are held by institutional investors. Comparatively, 95.6% of Intellia Therapeutics shares are held by institutional investors. 11.7% of Heska shares are held by insiders. Comparatively, 4.1% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Heska beats Intellia Therapeutics on 9 of the 14 factors compared between the two stocks.

Heska (NASDAQ:HSKA) and Riot Blockchain (NASDAQ:RIOT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings.

Volatility & Risk

Heska has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. Comparatively, Riot Blockchain has a beta of 4.56, suggesting that its stock price is 356% more volatile than the S&P 500.

Insider and Institutional Ownership

96.1% of Heska shares are owned by institutional investors. Comparatively, 9.0% of Riot Blockchain shares are owned by institutional investors. 11.7% of Heska shares are owned by insiders. Comparatively, 3.5% of Riot Blockchain shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Heska and Riot Blockchain's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations for Heska and Riot Blockchain, as provided by MarketBeat.

Heska currently has a consensus target price of $185.80, suggesting a potential upside of 8.22%. Riot Blockchain has a consensus target price of $28.00, suggesting a potential downside of 30.52%. Given Heska's higher possible upside, equities research analysts plainly believe Heska is more favorable than Riot Blockchain.

Valuation and Earnings

This table compares Heska and Riot Blockchain's top-line revenue, earnings per share (EPS) and valuation.

Heska has higher revenue and earnings than Riot Blockchain. Riot Blockchain is trading at a lower price-to-earnings ratio than Heska, indicating that it is currently the more affordable of the two stocks.

Summary

Heska beats Riot Blockchain on 10 of the 14 factors compared between the two stocks.

Myriad Genetics (NASDAQ:MYGN) and Heska (NASDAQ:HSKA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Insider & Institutional Ownership

96.7% of Myriad Genetics shares are owned by institutional investors. Comparatively, 96.1% of Heska shares are owned by institutional investors. 2.8% of Myriad Genetics shares are owned by company insiders. Comparatively, 11.7% of Heska shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations for Myriad Genetics and Heska, as provided by MarketBeat.

Myriad Genetics currently has a consensus price target of $17.20, suggesting a potential downside of 38.22%. Heska has a consensus price target of $185.80, suggesting a potential upside of 8.22%. Given Heska's stronger consensus rating and higher possible upside, analysts plainly believe Heska is more favorable than Myriad Genetics.

Earnings and Valuation

This table compares Myriad Genetics and Heska's revenue, earnings per share and valuation.

Heska has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Heska, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Myriad Genetics has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500. Comparatively, Heska has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.

Profitability

This table compares Myriad Genetics and Heska's net margins, return on equity and return on assets.

Summary

Heska beats Myriad Genetics on 10 of the 14 factors compared between the two stocks.

Lantheus (NASDAQ:LNTH) and Heska (NASDAQ:HSKA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends.

Volatility & Risk

Lantheus has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, Heska has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500.

Profitability

This table compares Lantheus and Heska's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Lantheus and Heska's top-line revenue, earnings per share and valuation.

Lantheus has higher revenue and earnings than Heska. Lantheus is trading at a lower price-to-earnings ratio than Heska, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

85.0% of Lantheus shares are held by institutional investors. Comparatively, 96.1% of Heska shares are held by institutional investors. 2.1% of Lantheus shares are held by company insiders. Comparatively, 11.7% of Heska shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Lantheus and Heska, as reported by MarketBeat.com.

Lantheus currently has a consensus target price of $23.6667, indicating a potential upside of 24.17%. Heska has a consensus target price of $185.80, indicating a potential upside of 8.22%. Given Lantheus' higher probable upside, equities research analysts clearly believe Lantheus is more favorable than Heska.

Summary

Lantheus beats Heska on 8 of the 14 factors compared between the two stocks.